Search Result

Results for "

RhoA Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (2) Akt (3) Angiotensin Receptor (2) Apoptosis (2) Autophagy (6) Calcium Channel (6) Endogenous Metabolite (1) Ferroptosis (3) HIV (4) HMG-CoA Reductase (HMGCR) (3) Influenza Virus (1) Isotope-Labeled Compounds (1) LPL Receptor (1) PI3K (3) PKA (6) PKC (6) Ras (10) ROCK (8) Tyrosinase (1)
By Research Areas:	Cancer (19) Cardiovascular Disease (6) Endocrinology (2) Inflammation/Immunology (4)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12646

Rhosin hydrochloride Maximum Cited Publications 24 Publications Verification	Ras Apoptosis	Cancer
Rhosin hydrochloride is a potent, specific RhoA subfamily Rho GTPases inhibitor. Rhosin hydrochloride specifically binds to RhoA to inhibit RhoA-GEF interaction with a K_d of ~ 0.4 uM, and does not interact with Cdc42 or Rac1, nor the GEF, LARG. Rhosin hydrochloride induces cell apoptosis . Rhosin hydrochloride promotes stress resiliency through enhancing D1-MSN plasticity and reducing hyperexcitability .

HY-145915A

(E/Z)-ZINC09659342	Ras	Cancer
(E/Z)-ZINC09659342 is an inhibitor of *Lbc-RhoA* interaction .

HY-15477

YS-49 5+ Cited Publications	Akt PI3K Angiotensin Receptor Adrenergic Receptor	Cardiovascular Disease Endocrinology
YS-49 is a PI3K/Akt (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits angiotensin II (Ang II)-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1. YS-49 is also an isoquinoline compound alkaloid, has a strong positive inotropic action through activation of cardiac β-adrenoceptors .

HY-109523

Cerivastatin sodium	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by *RhoA* inhibition, and has anti-cancer effect .

HY-108361

CCG-203971	Ras	Inflammation/Immunology Cancer
CCG-203971 is a second-generation Rho/MRTF/SRF pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC₅₀ =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC₅₀ of 4.2 μM. Potential anti-metastasis Agent .

HY-121667

Scaff10-8	ROCK	Cancer
Scaff10-8, bound to RhoA, inhibits the AKAP-Lbc-mediated *RhoA* activation .

HY-12646A

Rhosin	Ras Apoptosis	Cancer
Rhosin is a potent, specific RhoA subfamily Rho GTPases inhibitor, which specifically binds to RhoA to inhibit RhoA-GEF interaction with a K_d of ~ 0.4 uM, and does not interact with Cdc42 or Rac1, nor the GEF, LARG. Rhosin induces cell apoptosis . Rhosin promotes stress resiliency through enhancing D1-MSN plasticity and reducing hyperexcitability .

HY-145915

ZINC09659342	Ras	Cancer
ZINC09659342 (compound 13) is an inhibitor of *Lbc-RhoA* interaction with an IC₅₀ of 3.6 μΜ .

HY-158652

(R)-CCG-1423	Ras Akt PI3K	Cancer
(R)-CCG-1423 is an inhibitor of RhoA. (R)-CCG-1423 inhibits downstream of Rho and shows specificity for SRE .

HY-15477A

YS-49 monohydrate	Akt PI3K Angiotensin Receptor Adrenergic Receptor	Cardiovascular Disease Endocrinology
YS-49 (monohydrate) is a PI3K/Akt (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits angiotensin II (Ang II)-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1. YS-49 is also an isoquinoline compound alkaloid, has a strong positive inotropic action through activation of cardiac β-adrenoceptors .

HY-129458

Cerivastatin	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by *RhoA* inhibition, and has anti-cancer effect .

HY-12649

Y16 5 Publications Verification	Ras	Cancer
Y16 is a specific inhibitor of Leukemia-associated Rho guanine nucleotide exchange factor (LARG) with a K_d value of 76 nM. Y16 is active in blocking the interaction of LARG and related G-protein-coupled Rho GEFs with RhoA. Y16 shows no detectable effect on other diffuse B-cell lymphoma (Dbl) family Rho GEFs, Rho effectors, or a RhoGAP .

HY-113849

MLS-573151 1 Publications Verification MLS000573151	Ras	Inflammation/Immunology
MLS-573151 (MLS000573151) is a selective GTPase Cdc42 inhibitor with an EC₅₀ of 2 μM. MLS-573151 is inactive against other GTPases family members, such as Rab2, Rab7, H-Ras, Rac1, Rac 2 and RhoA wild-type. MLS-573151 acts by blocking the binding of GTP to Cdc42 .

HY-109523S

Cerivastatin-d3 sodium	Ferroptosis HMG-CoA Reductase (HMGCR) Isotope-Labeled Compounds	Cardiovascular Disease Cancer
Cerivastatin-d₃ sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by *RhoA* inhibition, and has anti-cancer effect .

HY-139061

Palmitoyl 3-carbacyclic phosphatidic acid	LPL Receptor ROCK	Cancer
Palmitoyl 3-carbacyclic phosphatidic acid (HY-139061) is a palmitoylated Carba-like cyclophosphatidic acid and an analog of lysophosphatidic acid (LPA). Palmitoyl 3-carbacyclic phosphatidic acid has different functions from LPA and can inhibit the activation of RhoA and inhibit the migration of melanoma cells. Palmitoyl 3-carbacyclic phosphatidic acid effectively inhibited experimental lung metastasis and reduced the number of tumor nodules in a B16-F0 xenograft mouse model .

HY-10341

Fasudil Hydrochloride 15+ Cited Publications HA-1077 Hydrochloride; AT-877 Hydrochloride	ROCK Calcium Channel Autophagy PKA PKC HIV	Cancer
Fasudil (HA-1077; AT877) Hydrochloride is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil Hydrochloride is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-10341A

Fasudil HA-1077; AT877	ROCK Calcium Channel Autophagy PKA PKC	Cancer
Fasudil (HA-1077; AT877) is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-10341C

Fasudil dihydrochloride HA-1077 dihydrochloride; AT-877 dihydrochloride	Calcium Channel ROCK PKA PKC Autophagy HIV	Cancer
Fasudil (HA-1077; AT877) dihydrochloride is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil dihydrochloride is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-10341B

Fasudil hydrochloride semihydrate HA-1077 hydrochloride semihydrate; AT877 hydrochloride semihydrate	ROCK Calcium Channel Autophagy HIV PKA PKC	Cancer
Fasudil (HA-1077; AT877) hydrochloride semihydrate is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil hydrochloride semihydrate is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-10341D

Fasudil mesylate HA-1077 mesylate; AT-877 mesylate	ROCK Calcium Channel Autophagy PKA PKC	Cancer
Fasudil (HA-1077; AT877) mesylate is a nonspecific and orally active *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil mesylate is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-10341R

Fasudil Hydrochloride (Standard)	ROCK Calcium Channel Autophagy PKA PKC HIV	Cancer
Fasudil (Hydrochloride) (Standard) is the analytical standard of Fasudil (Hydrochloride). This product is intended for research and analytical applications. Fasudil (HA-1077; AT877) Hydrochloride is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil Hydrochloride is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-115376

Z62954982 ZINC08010136	Ras	Inflammation/Immunology
Z62954982 (ZINC08010136) is a potent, selective and?cell-permeable Rac1 (IC₅₀=12 μM) inhibitor that is 4 times more effective than NSC23766 (HY-15723A) (IC₅₀=50 μM). Z62954982?disrupts the Rac1/Tiam1 complex and decreases cytoplasmic levels of active Rac1 (GTP-bound Rac1), without affecting the activity of other Rho GTPases (such as Cdc42 or RhoA) .

HY-I0400

N-Acetylneuraminic acid 3 Publications Verification NANA; Lactaminic acid	Tyrosinase Ras Influenza Virus Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Cancer
N-Acetylneuraminic acid (NANA; Lactaminic acid), a nonphenolic structure, is the predominant form of sialic from Collocalia esculenta. N-Acetylneuraminic acid plays a biological role in myocardial injury, melanoma and viral or bacterial infection. N-Acetylneuraminic acid inhibits melanogenesis by reducing tyrosinase activity and triggers myocardial injury in vitro and in vivo by activation of the Rho/Rho-associated signaling pathway through binding to *RhoA* and Cdc42. N-Acetylneuraminic acid may prevent high fat diet (HFD)-induced inflammation and oxidative stress, thereby prevents hyperlipidemia-associated inflammation and oxidative stress. N-Acetylneuraminic acid is promising for research in the field of melanoma, coronary artery, obesity-related diseases and hyperlipidemia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-I0400

N-Acetylneuraminic acid 3 Publications Verification NANA; Lactaminic acid	Cardiovascular Disease Structural Classification Microorganisms Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Saccharides Monosaccharides	Tyrosinase Ras Influenza Virus Endogenous Metabolite
N-Acetylneuraminic acid (NANA; Lactaminic acid), a nonphenolic structure, is the predominant form of sialic from Collocalia esculenta. N-Acetylneuraminic acid plays a biological role in myocardial injury, melanoma and viral or bacterial infection. N-Acetylneuraminic acid inhibits melanogenesis by reducing tyrosinase activity and triggers myocardial injury in vitro and in vivo by activation of the Rho/Rho-associated signaling pathway through binding to *RhoA* and Cdc42. N-Acetylneuraminic acid may prevent high fat diet (HFD)-induced inflammation and oxidative stress, thereby prevents hyperlipidemia-associated inflammation and oxidative stress. N-Acetylneuraminic acid is promising for research in the field of melanoma, coronary artery, obesity-related diseases and hyperlipidemia .

Cat. No.	Product Name	Chemical Structure

HY-109523S

Cerivastatin-d3 sodium
Cerivastatin-d₃ sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by *RhoA* inhibition, and has anti-cancer effect .

Cerivastatin-d3 sodium

Cerivastatin-d₃ sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks